Oncology

“These new therapies allow for treatment without some of the traditional chemotherapy agents.”

A fully human monoclonal antibody, cemiplimab targets the immune checkpoint receptor PD-1 on T cells, blocking cancer cells from using the PD-1 pathway to suppress T-cell activation.

Officials with the FDA have approved atezolizumab plus cobimetinib and vemurafenib for the treatment of patients with BRAF V600 mutation-positive advanced melanoma.

Isatuximab-ifrc is the third monoclonal antibody approved for the treatment of R/R MM.

The rarity of disease states coupled with novel medication mechanisms and high costs lead to complexities in accessing treatment and optimizing outcomes.

These study results were announced by Eisai and Merck during the 2020 American Society of Clinical Oncology Virtual Scientific Program, May 29-31.

As clinicians, we must first understand the unique challenges that a patient is facing and then tailor our support to address their specific needs.

Pharmacists can deliver value-based oncology services as an integral part of the health care team to improve patient outcomes.

Sarcomas account for about 1% of all adult cancers and 15% of all pediatric cancers.

Many pharmacies may be missing significant, profitable opportunities...via generic pharmaceuticals.

The investigators found that patients with preexisting neutropenia could be managed on venetoclax, although use of G-CSF would likely also be required in conjunction with the treatment.

Both premenopausal and postmenopausal breast cancer rates are rising globally.

Although the treatment of cancer is facing many challenges, the pandemic is also creating massive amounts of new data with which to educate patients, conduct new research, and make more informed clinical decisions.

This Pharmacy Times Webcast provides an overview of how the COVID-19 pandemic has impacted the treatment and management of patients with cancer.

Following initial breast cancer diagnosis by mammography, MRI, or ultrasound, treatment is largely based upon the histologic subtype and staging of the tumor(s).

Data aggregation partners can provide value in their ability to pull clinical information from both the HSSP and electronic health records.

Meaningful breakthrough therapies are receiving accelerated approval based on evidence of impact on a surrogate end point rather than evidence of impact on the actual clinical benefit for which the drug is intended.

Brexucabtagene autoleucel (Tecartus, Kite Pharma) is indicated for adult patients diagnosed with mantle cell lymphoma (MCL) who have not responded to or who have relapsed following other kinds of treatment.

Earlier results of the FAST trial, which was launched in 2004, found that reducing the number of radiotherapy fractions to 5 was feasible and safe in the short term.

Patients with cancer diagnosed more than 24 months ago are at an increased risk of severe COVID-19.

The selection of an agent for hyperglycemia management requires knowledge of both the efficacy and the potential adverse effects of each possible agent, so choosing the best therapy for any given patient can be complicated.

Data show that immunotherapy doesn’t necessarily worsen complications for patients with both COVID-19 and cancer.

In addition to its potential uses in cancer treatment, this novel drug delivery system could be used with magnetic resonance imaging or fluorescence imaging.

Pharmacists are central health care professionals in medication therapy management and play a crucial role in improving life quality outcomes among patients.

Results of the COVID-19 and Cancer Consortium cohort study were presented during the 2020 American Society of Clinical Virtual Scientific Program.

Cancer medications contribute substantially to the cost of health care in the United States, with 8 of the 10 most expensive drugs indicated for the treatment of cancer

Directions in Oncology PharmacyTM provides insight into how specialty pharmacies can improve transitional care during the COVID-19 pandemic.

With medicinal cannabis research in its infancy, many health care providers are unsure how to provide accurate counseling and appropriate treatment to their patients.

Leung added that this is the first study to show the potential beneficial effects of ACE inhibitors and ARBs on colorectal cancer development, based on a large group of patients who were colorectal cancer-free at the beginning of the study.

The presence of ctDNA and CTCs in the plasma of the blood of women who have undergone chemotherapy prior to surgery for the treatment of triple-negative breast cancer (TNBC) are critical indicators in the prediction of disease recurrence and disease-free survival.